Update from BIG 1-98, Studies on PARP Inhibitors, Bevacizumab & GI Perforation, Oral Mucositis, Casopitant in CINV, and more

Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer

Imulunestrant With/Without Abemaciclib Generates Improved PROs in ER+/HER2– Advanced Breast Cancer

Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanced NSCLC With c-MET Overexpression